The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: A Short Review
Abstract
This review describes the pathology, prognosis, current treatment options, and future directions for the management of patients with triple-negative breast cancer. "Triple-negative" tumors lack expression of estrogen and progesterone receptors, and HER2. The subtype comprises some 15% of all breast cancers, with tumors of a typically larger size and higher grade. Clinically, triple-negative breast cancer has a relatively high rate of recurrence and distant metastasis, and poor overall survival. The standard of care is chemotherapy, although recent research suggests a sound rationale for the use of targeted agents with antitumor and/or antiangiogenic activity such as receptor tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 1×
“Emerging preclinical data suggest that the RTK inhibitor dasatinib, which targets members of the SRC family of kinases, PDGFR, KIT, and BCR-ABL, may have efficacy in triple-negative and basal-like breast cancer.(49,50) A phase II clinical trial investigatFIGURE 4.”
Background
Cited by
Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
Pierobon, M., & Frankenfeld, C. L. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2339-3 · Cited by 357
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-Burow, B. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3192 · Cited by 260
The mitochondrial calcium uniporter regulates breast cancer progression via HIF ‐1α
Tosatto, A., Sommaggio, R., Kummerow, C., Bentham, R. B., Blacker, T. S., Berecz, T., Duchen, M. R., Rosato, A., Bogeski, I., Szabadkai, G., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606255 · Cited by 258
LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis
Wang, Y., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Guo, B., Zhang, S., Wu, R., Zhang, Z., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190950 · Cited by 231
Metadata
- Authors
- Elias, A. D.
- Venue
- American Journal of Clinical Oncology
- Published
- 2010-12
- Volume
- 33
- Issue
- 6
- Pages
- 637-645
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W1995036570
- Cited by
- 242
- References
- 2
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple-Negative Breast Cancer: A Short Review. https://app.cochat.ai/papers/10.1097/coc.0b013e3181b8afcf
- The paper
- Elias, A. D. (2010). Triple-Negative Breast Cancer: A Short Review. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0b013e3181b8afcf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.